Q-omics provides the consensus-scored RABL3 profile across patient tissues and cancer cell-line models. RABL3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RABL3 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RABL3 RNA expression shows 19,940 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where RABL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RABL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RABL3 survival associations across molecular data types. RABL3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RABL3 RNA expression–survival associations across cancer types. High RABL3 expression shows unfavorable associations in MESO, LGG, PAAD and LIHC, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RABL3 RNA expression.
This table summarizes RABL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RABL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RABL3 shows lower tumor expression in THCA, KICH, KIRP and KIRC and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher RABL3 RNA expression in normal versus tumor tissue (log2 FC = −1.467, t-test p < 0.001).
This table shows molecular features associated with RABL3 in patient tissues and cancer cell lines. In patient samples, RABL3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RABL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
